Welcome to our dedicated page for LifeStance Health Group news (Ticker: LFST), a resource for investors and traders seeking the latest updates and insights on LifeStance Health Group stock.
LifeStance Health Group reports developments as a Nasdaq-listed provider of virtual and in-person outpatient mental healthcare. The company serves children, adolescents and adults through psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy.
Recurring news themes include quarterly operating results, visit volumes, clinician productivity, center-level margin trends, cash flow, debt and capital allocation. Company updates also cover secondary common stock offerings by selling stockholders, share repurchase activity, investor conference presentations, executive and board changes, and corporate-status announcements tied to its outpatient mental health services business.
LifeStance Health Group, Inc. (NASDAQ: LFST) reported Q2 2022 revenue of $209.5 million, a 31% increase from the previous year. The total clinician count rose to 5,226, with a net gain of 237 in the quarter. Despite a net loss of $68.7 million, a slight improvement from the prior year's loss, adjusted EBITDA remained steady at $14.6 million. The company expects full-year revenue and center margin towards the lower end of previous guidance due to changes in clinician availability. Full-year adjusted EBITDA guidance was reaffirmed at $63 million to $67 million.
LifeStance Health Group, Inc. (NASDAQ: LFST) will release its second quarter earnings after market close on August 9, 2022. A live earnings conference call is scheduled for the same day at 4:30 p.m. Eastern Time, accessible via phone or a real-time audio webcast on the Investor Relations website. LifeStance, founded in 2017, is a leading provider of outpatient mental health care, employing around 5,000 professionals across 500 centers in 32 states. The company aims to enhance access to affordable mental health services for individuals of all ages.
LifeStance Health Foundation has appointed Gwen Booth as its first Executive Director, effective July 1, 2022. Booth will focus on enhancing access to mental health services for vulnerable populations, including youth and underrepresented communities. The Foundation has granted over $400,000 to various organizations aiming to destigmatize mental health care. Booth's background includes leadership roles in healthcare, and she aims to address barriers to affordable mental healthcare, advancing the Foundation's mission to unify mental and physical healthcare.
LifeStance Health Group, Inc. (NASDAQ: LFST), a leading outpatient mental health care provider, will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 11:20 a.m. PT. CEO Michael Lester, COO Danish Qureshi, and CFO J. Michael Bruff will present at the event moderated by Jamie Perse. Attendees can access the live webcast on LifeStance's Investor Relations website, where a replay will also be available. Danish Qureshi's appointment as COO takes effect on July 1, 2022.
LifeStance Health (NASDAQ: LFST) announces the retirement of COO Gwen Booth, who will become Executive Director of the LifeStance Health Foundation, which aims to improve mental health access. Danish Qureshi, previously Chief Growth Officer, has been appointed as the new COO effective July 1, 2022. Booth has been with the company since its founding in 2017. Qureshi has a strong track record in growing the company and enhancing mental health services. The Foundation, established in 2021, has already awarded over $400,000 to support mental health initiatives.
LifeStance Health (NASDAQ: LFST), a leading provider in outpatient mental health care, will present at the UBS Global Healthcare Conference on May 25, 2022. Presenters include CEO Michael Lester, CFO J. Michael Bruff, and Chief Growth Officer Danish Qureshi. The presentation is scheduled for 7:45 a.m. Eastern time and will be moderated by Kevin Caliendo. A live webcast will be available on the LifeStance Health Investor Relations website, with a replay following the event. LifeStance employs approximately 5,000 professionals across 32 states.
LifeStance Health Group, Inc. (NASDAQ: LFST) reported Q1 2022 revenue of $203.1 million, a 42% increase from the prior year. Total clinicians grew 51% to 4,989, with a net addition of 199 clinicians. However, net loss surged to $62.3 million, primarily due to stock-based compensation costs of $59.9 million. Adjusted EBITDA remained stable at $12.5 million. The company reaffirmed full-year 2022 revenue guidance of $865 million to $885 million.
LifeStance Health Group, Inc. (NASDAQ: LFST) is set to release its first quarter earnings on May 9, 2022, after market close. Following the earnings announcement, the company will conduct a conference call at 4:30 p.m. ET to discuss its financial performance. Interested participants can join via a toll-free number or listen to a live webcast through LifeStance's Investor Relations website. Founded in 2017, LifeStance is a major provider of outpatient mental health care, employing roughly 4,800 professionals across 32 states.
Summary not available.
LifeStance Health Group (LFST) reported a 61% revenue growth in Q4 2021, reaching $190.1 million, and a full-year revenue of $667.5 million, up 77% from 2020. However, the company posted a net loss of $108 million for Q4 and $307.2 million for the full year, primarily due to stock-based compensation. LifeStance anticipates a revenue growth rate in the low 30s for 2022, with expected revenue between $865 and $885 million. The company expanded its clinician base by 55% to 4,790 clinicians, demonstrating its ongoing growth strategy.